About the Company
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
133
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HOOK News
HOOKIPA Pharma Inc HOOK
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Hookipa Pharma Updates on Business Priorities and Partnerships
Hookipa Pharma Inc (HOOK) has released an update to notify the public and investors about a regulation fd disclosure. On January 29, 2024, the Company issued a press release providing updates on ...
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary ...
Hookipa Pharma Trims Workforce, Refocuses R&D Strategy
Hookipa Pharma Inc (HOOK) has released an update to notify the public and investors about termination and asset disposition expenses. HOOKIPA has decided to focus on developing HB-200 for HPV16 ...
All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy
HOOKIPA Pharma Inc. (HOOK) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
HOOKIPA Pharma Inc HOOK
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today ...
HOOKIPA Pharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Hookipa Pharma Inc (HOOK)
Galapagos (NASDAQ:GLPG) surged on... HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary ...
HOOKIPA Pharma Inc. (HOOK)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Hookipa Pharma Inc (HOOK)
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead ...
Loading the latest forecasts...